Comparative Pharmacology
Head-to-head clinical analysis: STALEVO 100 versus STALEVO 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STALEVO 100 versus STALEVO 200.
STALEVO 100 vs STALEVO 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stalevo 100 is a combination of carbidopa, levodopa, and entacapone. Levodopa is a precursor to dopamine that crosses the blood-brain barrier and is converted to dopamine by aromatic L-amino acid decarboxylase (AAAD), thereby increasing dopamine levels in the brain. Carbidopa inhibits peripheral AAAD, reducing the conversion of levodopa to dopamine outside the brain, which increases the amount of levodopa available for CNS entry and decreases side effects. Entacapone is a reversible inhibitor of catechol-O-methyltransferase (COMT), which reduces the metabolism of levodopa to 3-O-methyldopa, prolonging the half-life and duration of action of levodopa.
STALEVO 200 contains carbidopa, levodopa, and entacapone. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing levodopa availability to the brain. Levodopa is decarboxylated to dopamine in the brain, restoring dopaminergic activity in the striatum. Entacapone inhibits catechol-O-methyltransferase (COMT), reducing peripheral metabolism of levodopa and prolonging its half-life.
One tablet (carbidopa 25 mg / levodopa 100 mg / entacapone 200 mg) orally three to four times daily, maximum 8 tablets per day.
One tablet (levodopa 200 mg, carbidopa 50 mg, entacapone 200 mg) administered orally 3 to 4 times daily, adjusted based on response and tolerability.
None Documented
None Documented
Levodopa: 1.5-2 h (peripherally); with carbidopa: prolongs to ~2.5 h. Carbidopa: 2-3 h. Clinical context: requires continuous dopaminergic stimulation to avoid motor fluctuations.
Levodopa: 1.3 hours (with carbidopa). Entacapone: 0.4-0.7 hours. Carbidopa: 1-2 hours. Terminal half-life of levodopa is extended to ~1.5-2 hours in combination; clinical dosing is every 4-6 hours.
Renal: ~90% (levodopa metabolites), ~80% (carbidopa unchanged and metabolites); biliary/fecal: minimal
Carbidopa: 70% renal (unchanged and metabolites), 30% fecal. Levodopa: 70-80% renal (metabolites), <10% fecal. Entacapone: 90% fecal (unchanged and metabolites), 10% renal.
Category C
Category C
Anti-Parkinson Agent
Anti-Parkinson Agent